Dew, I wasn't addressing the aspect of whether the data-exclusivity period would have any affect on biotech innovation one way or the other. I had not given it a lot of thought, and just assumed that quote was what it looked like, a marketing position taken by those what want to protect their entrenched positions.
Surely if someone has a drug that has a very long period of protection, that company would find no reason to develop anything that could compete with their own drugs. Like the old ATT, they were happy with no competition and innovation was very slow.
My take was that maybe the rewards are way too high right now, and that is what drives so many failures Vs so few successes.
For instance, if oil were selling for $600 a barrow, a whole lot of dry wells would be drilled in the hopes of striking even a small producing well. Because the rewards are so high. The same for drug companies, the rewards of success are very high.
News 
Market Data 
Discover 
AI
